- Report
- January 2022
- 125 Pages
Global
From €2376EUR$2,500USD£2,022GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €3089EUR$3,250USD£2,628GBP
- Report
- January 2022
- 121 Pages
Global
From €4514EUR$4,750USD£3,841GBP
- Report
- August 2022
- 119 Pages
Global
From €4277EUR$4,500USD£3,639GBP
- Report
- April 2023
- 120 Pages
Global
From €4514EUR$4,750USD£3,841GBP
- Report
- June 2021
- 50 Pages
China
From €2471EUR$2,600USD£2,103GBP
- Report
- April 2021
China
From €2471EUR$2,600USD£2,103GBP
- Report
- June 2018
- 30 Pages
China
From €2091EUR$2,200USD£1,779GBP
- Report
- January 2024
- 93 Pages
Global
From €3500EUR$3,945USD£3,082GBP
- Report
- April 2023
- 160 Pages
Global
From €5701EUR$5,999USD£4,851GBP
- Report
- April 2023
- 147 Pages
Global
From €5701EUR$5,999USD£4,851GBP
- Report
- May 2023
- 252 Pages
Global
From €3393EUR$3,570USD£2,887GBP
Trastuzumab is a monoclonal antibody used to treat certain types of breast cancer. It is used to treat HER2-positive breast cancer, which is a type of cancer that has a higher than normal amount of a protein called HER2. Trastuzumab works by blocking the HER2 protein, which helps to slow or stop the growth of cancer cells. It is usually given in combination with other chemotherapy drugs. Trastuzumab is typically given intravenously, and can be used in both early and advanced stages of breast cancer. It is also used to reduce the risk of recurrence in patients who have already been treated for HER2-positive breast cancer.
Trastuzumab is a widely used drug in the treatment of breast cancer, and is available from a number of pharmaceutical companies. Some of the companies that produce trastuzumab include Roche, Merck, Pfizer, and Amgen. Show Less Read more
